overnight lowering free fatty acids acipimox improves insulin resistance glucose tolerance obese diabetic nondiabetic subjects pubmed ncbi abstract obesity commonly elevated plasma free fatty acid ffa levels insulin resistance hyperinsulinemia important cardiovascular risk factors insulin resistance hyperinsulinemia obesity remains uncertain tested hypothesis ffas link obesity insulin resistance/hyperinsulinemia lowering chronically elevated plasma ffa levels improve insulin resistance/hyperinsulinemia glucose tolerance obese nondiabetic diabetic subjects acipimox num mg long-acting antilipolytic drug placebo overnight num p m num a m num a m num lean control subjects num obese nondiabetic subjects num obese subjects impaired glucose tolerance num patients type num diabetes euglycemic-hyperinsulinemic clamps oral glucose tolerance tests num performed separate mornings overnight acipimox placebo treatment obese study groups acipimox lowered fasting levels plasma ffas num plasma insulin approximately num insulin-stimulated glucose uptake euglycemic-hyperinsulinemic clamping twofold higher acipimox placebo areas glucose insulin curves oral glucose tolerance testing approximately num lower acipimox administration placebo conclude lowering elevated plasma ffa levels reduce insulin resistance/hyperinsulinemia improve oral glucose tolerance lean obese nondiabetic subjects obese patients type num diabetes 
